Thoma Bravo, a leading software investment firm, today announced the completion of its strategic growth investment in Greenphire, the global leader in financial lifecycle management software for clinical trials.
Read More: Lithuanian Airports Now Offer Customers A Seamless Travel Search With An AI Assistant
“Today marks an important milestone for Greenphire and our entire community as we begin a new chapter and look to build upon our current successes,” said Jim Murphy, CEO of Greenphire. “We believe Thoma Bravo’s resources and deep healthcare IT knowledge will help Greenphire further capitalize on the growing demand for solutions to facilitate more efficient, effective and flexible clinical trials.”
“Greenphire has established itself as a trusted partner for an impressive array of sponsors, contract research organizations (CROs) and sites, as the importance of effective technology solutions is increasingly critical to successful clinical study execution,” said Hudson Smith, a Partner at Thoma Bravo. “We are thrilled to complete our investment in Greenphire and ready to begin our work together to accelerate the company’s growth trajectory.”
Read More: SalesTechStar Interview With Chris Polishuk, CRO At Lucidworks
“We are looking forward to working alongside Jim and the Greenphire team to help facilitate the expansion of Greenphire’s global client base and product offering, and further spur innovation across the company,” added AJ Jangalapalli, a Principal at Thoma Bravo.
Jefferies LLC and AGC Partners served as financial advisor to Greenphire and Jones Day served as legal counsel. William Blair served as financial advisor to Thoma Bravo and Kirkland & Ellis, LLP served as legal counsel.